Aarti Pharmalabs (AARTIPHARM) Fundamentals 2026 — P/E 32.7x, Revenue Analysis | SniperIQ
Aarti Pharmalabs (AARTIPHARM) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹6,098 Crore, trading at ₹673.35 on the BSE. This SniperIQ fundamentals page covers Aarti Pharmalabs's valuation (P/E 32.7x, P/B 2.9x), profitability (net margin 10.3%), revenue (₹1,819 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aarti Pharmalabs's market cap?
Aarti Pharmalabs (AARTIPHARM) has a market capitalization of approximately ₹6,098 Crore, trading at ₹673.35 on the BSE. Market cap moves with the live share price.
What is Aarti Pharmalabs's P/E ratio?
Aarti Pharmalabs's trailing twelve-month P/E ratio is 32.7x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aarti Pharmalabs?
Aarti Pharmalabs runs a net profit margin of 10.3%, a gross margin of 50.4%, and an operating margin of 16.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aarti Pharmalabs generate?
Aarti Pharmalabs reported revenue of ₹1,819 Crore for fiscal year 2026, with net income of ₹175 Crore and earnings per share (EPS) of 19.27. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aarti Pharmalabs pay a dividend?
Aarti Pharmalabs offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Aarti Pharmalabs financially healthy?
Aarti Pharmalabs carries a debt-to-equity ratio of 0.36x and a current ratio of 1.49x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aarti Pharmalabs a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aarti Pharmalabs (AARTIPHARM) the key facts are: market cap ₹6,098 Crore, P/E 32.7x, revenue ₹1,819 Crore, 52-week range 583.85-969.05. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aarti Pharmalabs's full fundamentals live
Get Aarti Pharmalabs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.